Cabbacis LLC, a tobacco product manufacturer and biotech company, has received a patent from the European Patent Office (EPO) for vaporizer pods used with oral electronic vaporizers. The patent, which includes 9 claims, expires in 2040 and covers vaporizer pods made from blends of very-low-nicotine tobacco and hemp. The company's patented pods and very-low-nicotine cigarettes are designed to help smokers of conventional cigarettes reduce their intake, transition to less harmful products, or quit nicotine altogether.
According to Joseph Pandolfino, the Founder and President of Cabbacis, the majority of the world's 1.1 billion cigarette smokers want to smoke less, quit, or switch to safer alternatives. Very-low-nicotine tobacco products can serve as a bridge to a healthier lifestyle. These products, which have been evaluated in numerous clinical studies, contain about 95 percent less nicotine than regular cigarettes. The studies have shown that smokers of very-low-nicotine cigarettes smoke fewer cigarettes per day, have reduced nicotine dependence and exposure, make more quit attempts, and have more smoke-free days.
Pandolfino also mentioned that the addition of hemp flower to low-nicotine tobacco improves the taste of the products and is expected to enhance their effectiveness due to the presence of non-THC cannabinoids. Cabbacis is growing commercially a flue-cured tobacco this year that is expected to have a reduced-nicotine content of approximately 95 percent compared to conventional tobacco. This allows the company to have more flexibility in product development and commercialization.
The issuance of the patent means Cabbacis now has patented products in key tobacco markets including the United States, Europe, and China. The company aims to provide smokers with safer alternatives and help them make the transition to a healthier lifestyle. With the growing demand for harm reduction products, Cabbacis is well-positioned to lead the market in this area.
Reference:
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
